Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma
Figure 1
Axial contrast enhanced CT images show a peritoneal deposit within the left side of the abdomen (arrows). Prior to commencing sirolimus, the deposit progressed by RECIST 1.1 over a period of 6 months ((a) and (b)). CT staging at 4 months (c) and 13 months (d) on treatment with sirolimus showed that the deposit had reduced in size but was within the limits of stable disease by RECIST v1.1. A further pelvic deposit (not shown) also reduced in size but overall disease remained stable by RECIST v1.1. However, assessment by Choi criteria which incorporates attenuation changes classified disease status as partial response at 4 months and further partial response at 13 months.
